Drug intelligence / Profile preview

EBP11

Development stage: Phase 2
Lead developer: Entera Bio
Administration: Oral

Overview

EBP11 is an investigational oral drug formulation developed by Entera Bio. Its mechanism of action is currently unknown, and it does not represent a novel mechanism. EBP11 has been studied as a modified oral formulation in clinical trials comparing the pharmacokinetics of human parathyroid hormone (hPTH 1-34) with other formulations such as EBP22, EBP05, and subcutaneous Forteo. The primary indications under investigation include osteoporosis and hypoparathyroidism[1][4]. As of now, there are no approved indications or known adverse events associated with this drug.

Beyond the preview

Go deeper on EBP11.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EBP11.

Explore the full profile